Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Alzheimer’s disease has afflicted Hannah Richardson’s family for generations. A rare genetic mutation, passed down from her ...

Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Eli Lilly previously said that phase three study was expected to finish in February ... "We believe this potential new medicine can deliver even more weight loss than tirzepatide and it could ...